These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15517414)

  • 1. Calcimimetics--fooling the calcium receptor.
    Ritz E
    Pediatr Nephrol; 2005 Jan; 20(1):15-8. PubMed ID: 15517414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical application of calcimimetics].
    Nishi H; Fukagawa M
    Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2008 Jan; 18(1):20-6. PubMed ID: 18175867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
    Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
    J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient.
    Komaba H; Shin J; Fukagawa M
    Nephrol Dial Transplant; 2010 Feb; 25(2):638-41. PubMed ID: 19892751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects of calcimimetics in hyperparathyroidism.
    Peacock M
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):414-5. PubMed ID: 15758287
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent updates on the calcium-sensing receptor as a drug target.
    Trivedi R; Mithal A; Chattopadhyay N
    Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parathyroid and bone. Calcimimetics and bone metabolism].
    Fukumoto S
    Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
    Sułowicz W
    Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.